Blood-based identification of non-responders to anti-TNF therapy in rheumatoid arthritis

BMC Medical Genomics

Volumn 8, Issue 1, 2015, Pages

  Thomson, Ty M ^a   Lescarbeau, Reynald M ^a   Drubin, David A ^a   Laifenfeld, Daphna ^a   De Graaf, David ^a   Fryburg, David A ^a   Littman, Bruce ^b   Deehan, Renée ^a   Van Hooser, Aaron ^a  

^a Selventa   (United States)

^b Translational Medicine Associates   (United States)

Author keywords

Anti TNF therapy; Classifier; Infliximab; Rheumatoid arthritis

Indexed keywords

CALGRANULIN A; CALGRANULIN B; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA SECRETASE; HEPATOCYTE NUCLEAR FACTOR 3BETA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLIXIMAB; INTERLEUKIN 11; NORADRENALIN; SULINDAC SULFIDE; TUMOR NECROSIS FACTOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT;

ARTICLE; ASSESSMENT OF HUMANS; CLASSIFIER; DRUG EFFICACY; DRUG RESPONSE; ERBB2 GENE; EUROPEAN LEAGUE AGAINST RHEUMATISM RESPONSE CRITERIA; FOXA2 GENE; GAMMA SECRETASE COMPLEX GENE; GENE; GENE EXPRESSION; GENE EXPRESSION CLASSIFIER; HIF1A GENE; HUMAN; IL11 GENE; INSTRUMENT VALIDATION; MAP2K3 GENE; MEASUREMENT PRECISION; MEIS1 GENE; MST1R GENE; NF KB GENE; NF1 GENE; NOREPINEPHRINE GENE; NOS2 GENE; NR2F6 GENE; PATIENT IDENTIFICATION; PPARG GENE; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; S100A8 S100A9 GENE; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TNF GENE; VALIDATION STUDY; ALGORITHM; ANTAGONISTS AND INHIBITORS; AREA UNDER THE CURVE; ARTHRITIS, RHEUMATOID; BLOOD; COHORT ANALYSIS; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC DATABASE; SOFTWARE; STATISTICAL MODEL; TREATMENT OUTCOME;

ALGORITHMS; ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; COHORT STUDIES; DATABASES, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; INFLIXIMAB; LOGISTIC MODELS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SOFTWARE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84930640113     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/s12920-015-0100-6     Document Type: Article

References (42)

1. Maini RN, Feldmann M. How does infliximab work in rheumatoid arthritis? Arthritis Res. 2002;4 Suppl 2:S22-8.
2. Gibbons LJ, Hyrich KL. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response. BioDrugs. 2009;23(2):111-24.
3. Mewar D, Wilson AG. Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors. Br J Pharmacol. 2011;162(4):785-91.
4. Prajapati R, Plant D, Barton A. Genetic and genomic predictors of anti-TNF response. Pharmacogenomics. 2011;12(11):1571-85.
5. Atzeni F, Benucci M, Salli S, Bongiovanni S, Boccassini L, Sarzi-Puttini P. Different effects of biological drugs in rheumatoid arthritis. Autoimmun Rev. 2013;12(5):575-9.
6. Kumar P, Banik S. Pharmacotherapy options in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord. 2013;6:35-43.
7. Paula FS, Alves JD. Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis. Biologics. 2014;8:1-12.
8. Lequerre T, Gauthier-Jauneau AC, Bansard C, Derambure C, Hiron M, Vittecoq O, et al. Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res Ther. 2006;8(4):R105.
9. Sekiguchi N, Kawauchi S, Furuya T, Inaba N, Matsuda K, Ando S, et al. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab. Rheumatol Oxf. 2008;47(6):780-8.
10. Julia A, Erra A, Palacio C, Tomas C, Sans X, Barcelo P, et al. An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis. PLoS One. 2009;4(10):e7556.
11. Tanino M, Matoba R, Nakamura S, Kameda H, Amano K, Okayama T, et al. Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells. Biochem Biophys Res Commun. 2009;387(2):261-5.
12. Stuhlmuller B, Haupl T, Hernandez MM, Grutzkau A, Kuban RJ, Tandon N, et al. CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2010;87(3):311-21.
13. Sanayama Y, Ikeda K, Saito Y, Kagami S, Yamagata M, Furuta S, et al. Prediction of therapeutic responses to tocilizumab in patients with rheumatoid arthritis: biomarkers identified by analysis of gene expression in peripheral blood mononuclear cells using genome-wide DNA microarray. Arthritis Rheumatol. 2014;66(6):1421-31.
14. Sellam J, Marion-Thore S, Dumont F, Jacques S, Garchon HJ, Rouanet S, et al. Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial. Arthritis Rheumatol. 2014;66(8):2015-25.
15. Simon R, Radmacher MD, Dobbin K, McShane LM. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst. 2003;95(1):14-8.
16. Toonen EJ, Gilissen C, Franke B, Kievit W, Eijsbouts AM, den Broeder AA, et al. Validation study of existing gene expression signatures for anti-TNF treatment in patients with rheumatoid arthritis. PLoS One. 2012;7(3):e33199.
17. Martin F, Thomson TM, Sewer A, Drubin DA, Mathis C, Weisensee D, et al. Assessment of network perturbation amplitude by applying high-throughput data to causal biological networks. BMC Syst Biol. 2012;6(1):54.
18. Team RC. R: A Language and Environment for Statistical Computing [Internet]. 2013. Available from: http://www.R-project.org
19. R. Gentleman V. Carey S. Dudoit R. Irizarry W. Huber (eds)
20. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 2005;33(20):e175.
21. Catlett NL, Bargnesi AJ, Ungerer S, Seagaran T, Ladd W, Elliston KO, et al. Reverse causal reasoning: applying qualitative causal knowledge to the interpretation of high-throughput data. BMC Bioinformatics. 2013;14(1):340.
22. Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1-22.
23. Petersen D, Chandramouli GV, Geoghegan J, Hilburn J, Paarlberg J, Kim CH, et al. Three microarray platforms: an analysis of their concordance in profiling gene expression. BMC Genomics. 2005;6:63.
24. Russ J, Futschik ME. Comparison and consolidation of microarray data sets of human tissue expression. BMC Genomics. 2010;11:305.
25. Kim J-H. Estimating classification error rate: Repeated cross-validation, repeated hold-out and bootstrap. Comput Stat Data Anal [Internet]. 2009;53(11).
26. Van Riel PL, van Gestel AM, van de Putte LB. Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers. Br J Rheumatol. 1996;35 Suppl 2:4-7.
27. Liu CC, Hu J, Kalakrishnan M, Huang H, Zhou XJ. Integrative disease classification based on cross-platform microarray data. BMC Bioinformatics. 2009;10 Suppl 1:S25.
28. Min JL, Barrett A, Watts T, Pettersson FH, Lockstone HE, Lindgren CM, et al. Variability of gene expression profiles in human blood and lymphoblastoid cell lines. BMC Genomics. 2010;11:96.
29. Joehanes R, Johnson AD, Barb JJ, Raghavachari N, Liu P, Woodhouse KA, et al. Gene expression analysis of whole blood, peripheral blood mononuclear cells, and lymphoblastoid cell lines from the Framingham heart study. Physiol Genomics. 2012;44(1):59-75.
30. Chen J, Bardes EE, Aronow BJ, Jegga AG. ToppGene suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res. 2009;37(Web Server issue):W305-11.
31. Kawatkar AA, Jacobsen SJ, Levy GD, Medhekar SS, Venkatasubramaniam KV, Herrinton LJ. Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the medical expenditure panel survey. Arthritis Care Res Hoboken. 2012;64(11):1649-56.
32. Toms TE, Symmons DP, Kitas GD. Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors. Curr Vasc Pharmacol. 2010;8(3):301-26.
33. Toms TE, Panoulas VF, Kitas GD. Dyslipidaemia in rheumatological autoimmune diseases. Open Cardiovasc Med J. 2011;5:64-75.
34. Curtis JR, John A, Baser O. Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy. Arthritis Care Res. 2012;64(9):1282-91.
35. Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Llorca J. Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy. Ann N Y Acad Sci. 2010;1193:153-9.
36. Van Baarsen LG, Wijbrandts CA, Rustenburg F, Cantaert T, van der Pouw Kraan TC, Baeten DL, et al. Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis Res Ther. 2010;12(1):R11.
37. MacIsaac KD. GSE58795: Whole blood gene expression profiling of rheumatoid arthritis patients. 2014 [Internet]. 2014 [cited 2014 Sep 22]. Available from: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE58795
38. Merck Sharp & Dohme Corp. A Study to Evaluate the Effectiveness of Infliximab and Changes in Hand and Wrist Magnetic Resonance Imaging (MRI) in Participants With Active Rheumatoid Arthritis (RA). [Internet]. 2011 [cited 2014 Sep 22]. Available from: http://clinicaltrials.gov/ct2/show/study/NCT01313520
39. Mesko B, Poliska S, Vancsa A, Szekanecz Z, Palatka K, Hollo Z, et al. Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease. Genome Med. 2013;5(6):59.
40. Mesko B, Poliska S, Szamosi S, Szekanecz Z, Podani J, Varadi C, et al. Peripheral blood gene expression and IgG glycosylation profiles as markers of tocilizumab treatment in rheumatoid arthritis. J Rheumatol. 2012;39(5):916-28.
41. Raterman HG, Vosslamber S, de Ridder S, Nurmohamed MT, Lems WF, Boers M, et al. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther. 2012;14(2):R95.
42. Bansard C, Lequerré T, Derambure C, Vittecoq O, Hiron M, Daragon A, et al. Gene profiling predicts rheumatoid arthritis responsiveness to IL-1Ra (anakinra). Rheumatol Oxf Engl. 2011;50(2):283-92.